Literature DB >> 27040133

Variable levels of apoptotic signal-associated cytokines in the disease course of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.

Yongsheng Yang1, Feng Li1, Juan Du1, Yanyun Shen1, Jinran Lin1, Xiaohua Zhu1, Xiaoqun Luo1, Jun Liang1, Jinhua Xu1.   

Abstract

BACKGROUND/
OBJECTIVES: Keratinocyte death is a hallmark of Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN). Apoptotic signal-associated cytokines, such as TNF-α, sFasL, granulysin, sTRAIL and IFN-γ have been reported to participate in keratinocyte apoptosis. However, their levels are variable, which hampers the elucidation of the role of these cytokines. We sought to determine whether cytokine levels vary with disease course.
METHODS: The serum cytokine levels of 24 patients and blister fluid of 10 were analysed by enzyme-linked immunosorbent assay on the first day of their admission to hospital and were evaluated at different time points in the disease course. Meanwhile, surface markers (CD3, CD4, CD8, CD1a, CD14, CD16+56 and CD68) of blister fluid cells were measured by flow cytometry.
RESULTS: The concentrations of all cytokines in the serum and blister fluid were higher than those in the controls and were more elevated in the blister fluid than in the serum. Moreover, sTRAIL, IFN-γ and TNF-α quantities were relatively stable, while those of sFasL and granulysin decreased rapidly in the disease course. On the first day, CD8+ T and natural killer cells were predominant in the blister fluid but their relative percentage diminished gradually, while that of CD14+ cells increased.
CONCLUSION: Our study confirmed there are high but variable levels of these cytokines in SJS/TEN, especially in the early phase and different tendencies are manifested in the disease course.
© 2016 The Australasian College of Dermatologists.

Entities:  

Keywords:  Stevens-Johnson syndrome; apoptosis; keratinocyte; toxic epidermal necrolysis

Mesh:

Substances:

Year:  2016        PMID: 27040133     DOI: 10.1111/ajd.12462

Source DB:  PubMed          Journal:  Australas J Dermatol        ISSN: 0004-8380            Impact factor:   2.875


  7 in total

Review 1.  Biomarkers of adverse drug reactions.

Authors:  Daniel F Carr; Munir Pirmohamed
Journal:  Exp Biol Med (Maywood)       Date:  2017-09-26

2.  Mutant GNLY is linked to Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors:  Dora Janeth Fonseca; Luz Adriana Caro; Diana Carolina Sierra-Díaz; Carlos Serrano-Reyes; Olga Londoño; Yohjana Carolina Suárez; Heidi Eliana Mateus; David Bolívar-Salazar; Ana Francisca Ramírez; Alejandra de-la-Torre; Paul Laissue
Journal:  Hum Genet       Date:  2019-10-14       Impact factor: 4.132

Review 3.  Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances.

Authors:  Teresa Bellón
Journal:  Drug Saf       Date:  2019-08       Impact factor: 5.228

Review 4.  Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Authors:  Marianne Lerch; Carlo Mainetti; Benedetta Terziroli Beretta-Piccoli; Thomas Harr
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 10.817

5.  IL-15/IL-15Rα in SJS/TEN: Relevant Expression of IL15 and IL15RA in Affected Skin.

Authors:  Teresa Bellón; Olga González-Valle; Elena Sendagorta; Victoria Lerma; Javier Martínez Del Río; Celia Martínez; Guillermo Servera; Carlos González-Herrada; Lucía Cachafeiro; José A Lorente; Rosario Cabañas; Pedro Herranz; Francisco de Abajo
Journal:  Biomedicines       Date:  2022-08-02

6.  Association of interleukin-6 and tumor necrosis factor-α with mortality in hospitalized patients with cancer.

Authors:  Joseph R Stoll; Toral S Vaidya; Shoko Mori; Stephen W Dusza; Mario E Lacouture; Alina Markova
Journal:  J Am Acad Dermatol       Date:  2020-03-12       Impact factor: 11.527

Review 7.  The important role of non-covalent drug-protein interactions in drug hypersensitivity reactions.

Authors:  Werner J Pichler
Journal:  Allergy       Date:  2021-06-14       Impact factor: 14.710

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.